A Descamps

Biographic Data

ID7863534
NAMEA Descamps
GIVEN NAMESA
FAMILY NAMEDescamps
SIGNATUREDESCAMPS A
AFFILIATIONSInserm
ORCID0000-0003-2437-7876
VERIFIEDYes
TOTAL WORKS2
TOTAL CITATIONS0
WORKS AS AUTHOR2
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2021
LATEST PUBLICATION YEAR2023
H-INDEX0

  • Brand-specific estimates of influenza vaccine effectiveness for the 2021–2022 season in Europe

    Open AccessAnke L Stuurman, Antonio Losa Carmona et al.ARTICLEFrontiers in Public Health2023

    Introduction: Development of Robust and Innovative Vaccine Effectiveness (DRIVE) was a European public-private partnership (PPP) that aimed to provide annual, brand-specific estimates of influenza vaccine effectiveness (IVE) for regulatory and public health purposes. DRIVE was launched in 2017 under the umbrella of the Innovative Medicines Initiative (IMI) and conducted IVE studies from its pilot season in 2017-2018 to its final season in 2021-20…

  • Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the Covid-19 Emergence

    Open AccessAntonio Losa Carmona, Antonio Carmona et al.ARTICLEInternational Journal of…2021

    The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project is a public-private partnership aiming to build capacity in Europe for yearly estimation of brand-specific influenza vaccine effectiveness (IVE). DRIVE is a five-year project funded by IMI (Innovative Medicines Initiative). It was initiated as a response to the guidance on influenza vaccines by EMA (European Medicines Agency), which advised vaccine manufacturers to wor…